1. Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome 
Onur Keskin, Heiner Wedemeyer, Ali Tüzün, Kalliopi Zachou, Xheni Deda, George N. Dalekos, Benjamin Heidrich, Selcen Pehlivan, Stefan Zeuzem, Kendal Yalçın, Selim Gürel, Fehmi Tabak, Ramazan Idilman, Hakan Bozkaya, Michael Manns, Cihan Yurdaydin 
Clinical Gastroenterology and Hepatology 
Volume 13, Issue 13, Pages e2 (December 2015)
DOI: /j.cgh
Copyright © Terms and Conditions

2. Figure 1
A significant difference was observed in (A) HDV RNA and (B) quantitative HBsAg levels throughout the treatment and post-treatment follow-up period between post-treatment week 24 virologic responders vs nonresponders to pegylated interferon treatment. tx, treatment.
Clinical Gastroenterology and Hepatology  , e2DOI: ( /j.cgh )
Copyright © Terms and Conditions

3. Figure 2
End-of-treatment virologic response to treatment prediction based on on-treatment week 24 (A) HDV RNA detectability and (B) quantitative HBsAg decrease. (A) Four patients had missing HDV RNA data and (B) 5 patients had missing quantitative HBsAg levels. End-of-treatment virologic null response to treatment prediction based on cut-off values of (C) 1 and (E) 2 log decreases of on-treatment week 24 HDV RNA, and (D) combined use of HDV RNA and HBsAg decrease.
Clinical Gastroenterology and Hepatology  , e2DOI: ( /j.cgh )
Copyright © Terms and Conditions

4. Figure 3
Post-treatment week 24 virologic response to treatment prediction based on on-treatment week 24 HDV RNA and quantitative HBsAg levels. In 3 patients HDV RNA data were missing.
Clinical Gastroenterology and Hepatology  , e2DOI: ( /j.cgh )
Copyright © Terms and Conditions

5. Supplementary Figure 1
Flow diagram of patient numbers at baseline, end of treatment, and end of follow-up period.
Clinical Gastroenterology and Hepatology  , e2DOI: ( /j.cgh )
Copyright © Terms and Conditions